Cite
Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma
MLA
Marion Oberlé, et al. “Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma.” JCO Precision Oncology, vol. 6, Mar. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....43f6f46bfa8d84590834cc599b7564d7&authtype=sso&custid=ns315887.
APA
Marion Oberlé, Philippe Jamme, Sandrine Mansard, Laurent Machet, Alice Hervieu, Nora Kramkimel, Anna Greliak, Anne Sophie Jarrousse, Valentin Derangère, David Dudoignon, Clotilde Descarpentries, & Laurent Mortier. (2022). Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma. JCO Precision Oncology, 6.
Chicago
Marion Oberlé, Philippe Jamme, Sandrine Mansard, Laurent Machet, Alice Hervieu, Nora Kramkimel, Anna Greliak, et al. 2022. “Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma.” JCO Precision Oncology 6 (March). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....43f6f46bfa8d84590834cc599b7564d7&authtype=sso&custid=ns315887.